Emergent BioSolutions Inc
Company Profile
Business description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Contact
300 Professional Drive
GaithersburgMD20879
USAT: +1 240 631-3200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
900
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
stocks
What did Morningstar subscribers buy and sell in April?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.60 | 46.70 | -0.52% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 61,409.29 | 1,244.76 | -1.99% |
| NZX 50 Index | 12,965.01 | 60.06 | -0.46% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,630.80 | 42.70 | -0.49% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |